Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Internal Medicine

Background:

• Oral anticoagulant therapy initiation can be challenging, with variable patient responses.
• Previous trials on algorithm-guided dosing for oral anticoagulants have yielded inconsistent results.
• Personalized dosing strategies are needed to optimize anticoagulation therapy.

Purpose of the Study:

• To compare the effectiveness of a genotype-guided algorithm versus physician management for initiating acenocoumarol therapy.
• To evaluate the impact of pharmacogenetic dosing on achieving a steady dose and therapeutic international normalized ratio (INR).

Main Methods:

• A prospective, randomized study comparing standard care (SC) with genotype-guided dosing (PGx) for acenocoumarol initiation in atrial fibrillation patients.
• The PGx group utilized genetic data (VKORC1, CYP2C9, CYP4F2) in their dosing algorithm.
• Primary outcomes included time to steady dose, percentage of therapeutic INRs, and proportion of steadily anticoagulated patients over 90 days and 6 months.

Main Results:

• 39% of PGx patients reached a steady dose compared to 25% in SC (p=0.038).
• The PGx group achieved therapeutic INR levels faster (p=0.033) and had a higher percentage of therapeutic INRs (50% vs 45%, p=0.046).
• Significantly more PGx patients remained steadily anticoagulated at 6 months (p=0.010).

Conclusions:

• Genotype-guided dosing significantly improved the percentage of patients achieving a steady dose compared to routine physician management.
• Pharmacogenetic dosing enhances the efficiency and safety of initiating acenocoumarol therapy.
• This study supports the use of genotype-guided algorithms for personalized oral anticoagulation.